PMID- 20382839
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20151119
IS  - 1945-1997 (Electronic)
IS  - 0098-6151 (Linking)
VI  - 110
IP  - 3 Suppl 2
DP  - 2010 Mar
TI  - The physiologic role of incretin hormones: clinical applications.
PG  - S8-S14
AB  - Treatment of patients with type 2 diabetes mellitus (T2DM) traditionally has 
      involved a progression of phases, from conventional lifestyle interventions and 
      monotherapy, to combination therapy involving oral agents, to insulin initiation 
      and its use either alone or with oral pharmacotherapy. Currently, the need for 
      antidiabetic therapies with fewer adverse effects (eg, weight gain, reduced rates 
      of hypoglycemia) is unmet. In addition, most treatments fail to adequately 
      control postprandial hyperglycemia. Traditional options have generally been 
      directed at the "insulin demand" aspect and have targeted insulin secretion or 
      insulin resistance in peripheral tissues. Only recently have agents been 
      available to address the "glucose supply" aspect that leads to fasting 
      hyperglycemia in patients with T2DM. Incretin-based therapies, however, address 
      both aspects. Two classes of incretin-directed therapies are available and work 
      by either increasing endogenous levels of glucagon-like peptide-1 (GLP-1) (ie, 
      dipeptidyl peptidase-4 inhibitors) or by mimicking the activity of endogenous 
      GLP-1 (ie, GLP-1 agonists). These therapies treat the key metabolic abnormalities 
      associated with T2DM but do so with reduced rates of hypoglycemia and do not 
      promote weight gain as compared with conventional therapies.
FAU - Cefalu, William T
AU  - Cefalu WT
AD  - Pennington Biomedical Research Center in Baton Rouge, Louisiana, LA, USA. 
      william.cefalu@pbrc.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
RN  - 0 (Dipeptides)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Incretins)
RN  - 0 (Piperidines)
RN  - 0 (Pyrazines)
RN  - 0 (Triazoles)
RN  - 56HH86ZVCT (Uracil)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9GB927LAJW (saxagliptin)
RN  - JHC049LO86 (alogliptin)
RN  - PJY633525U (Adamantane)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Adamantane/analogs & derivatives/therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy/physiopathology/prevention & control
MH  - Dipeptides/therapeutic use
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Disease Progression
MH  - Gastric Inhibitory Polypeptide/physiology/therapeutic use
MH  - Glucagon-Like Peptide 1/agonists/biosynthesis/*therapeutic use
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Incretins/agonists/biosynthesis/physiology/*therapeutic use
MH  - Piperidines/therapeutic use
MH  - Pyrazines/therapeutic use
MH  - Sitagliptin Phosphate
MH  - Triazoles/therapeutic use
MH  - Uracil/analogs & derivatives/therapeutic use
RF  - 39
EDAT- 2010/04/23 06:00
MHDA- 2010/08/25 06:00
CRDT- 2010/04/13 06:00
PHST- 2010/04/13 06:00 [entrez]
PHST- 2010/04/23 06:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
AID - 110/3_suppl_2/S8 [pii]
PST - ppublish
SO  - J Am Osteopath Assoc. 2010 Mar;110(3 Suppl 2):S8-S14.